HLB Pharmaceutical's Nine-Month Revenue Up 34% YoY to 190.4 Billion Won

Cumulative operating profit: 1.85 billion won
Up 707.5% year on year

HLB Pharmaceutical said on November 13 that its consolidated revenue for the first nine months of this year rose 34.0% year on year to 190.4 billion won. Operating profit for the period increased 707.5% to 1.85 billion won.

Standalone revenue for the third quarter rose 3.1% year on year to 62.5 billion won, while operating profit came to 850 million won.

HLB Pharmaceutical company logo image. HLB Pharmaceutical

By business segment, revenue from ethical drugs (ETC) rose 11.5% year on year to 104.6 billion won. Contract manufacturing (CMO) revenue increased 9.0% to 5.26 billion won, while consumer healthcare revenue grew 40.3% to 16.4 billion won.

Shinhwa Advance, a pharmaceutical distribution subsidiary, also continued to grow. Its revenue for the first nine months of the year rose 18.0% to 65.987 billion won, compared with 55.916 billion won in the same period a year earlier.

HLB Pharmaceutical plans to focus on expanding revenue in its key business segments and strengthening its production competitiveness. In particular, it aims to expand its annual pharmaceutical production capacity to 700 million tablets, centered on its new Hyangnam plant. The company plans to cut manufacturing costs and improve profitability by shifting externally contracted production to its own facilities.

An HLB Pharmaceutical official said, "We are continuing to grow as revenue increases across our key business segments," adding, "We will continue to build a stable foundation for growth by strengthening our production competitiveness and improving profitability."

This content was produced with the assistance of AI translation services.